Photo: markets.businessinsider.com
Biogen Expands Immunology Portfolio with Exclusive License for Oral Inflammation Target
Biogen has secured an exclusive license for an oral C5aR1 antagonist from Vanqua Bio, enhancing its immunology portfolio to target neutrophil-driven inflammation linked to various diseases.
- On October 24, 2025, Biogen announced a license agreement with Vanqua Bio for exclusive worldwide rights to a preclinical oral C5aR1 antagonist aimed at treating inflammation.
- This oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a key mechanism in several inflammatory diseases, marking a significant advancement in Biogens drug development strategy.
- With this agreement, Biogen strengthens its position in the immunology sector by advancing innovative treatments that target the underlying causes of inflammation.
Por Qué Es Relevante
This collaboration underscores Biogens commitment to leading advancements in immunology, potentially offering new therapeutic options for patients suffering from chronic inflammatory diseases. The focus on oral administration could enhance patient compliance and accessibility.